Current and emerging therapies in multiple sclerosis: a systematic review

Ther Adv Neurol Disord. 2012 Jul;5(4):205-20. doi: 10.1177/1756285612450936.


Multiple sclerosis (MS) is a potentially disabling chronic autoimmune neurological disease that mainly affects young adults. Our understanding of the pathophysiology of MS has significantly advanced in the past quarter of a century. This has led to the development of many disease-modifying therapies (DMTs) that prevent exacerbations and new lesions in patients with relapsing remitting MS (RRMS). So far there is no drug available that can completely halt the neurodegenerative changes associated with the disease. It is the purpose of this review to provide concise information regarding mechanism of action, indications, side effects and safety of Food and Drug Administration and European Medicines Agency approved agents for MS, emerging therapies, and drugs that can be considered for off-label use in MS.

Keywords: disease-modifying therapies; emerging therapies; fingolimod; glatiramer acetate; interferon β; multiple sclerosis; natalizumab.